UBS Group’s Aimei Health Technology Co Right AFJKR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-2,447
Closed -$754 10410
2026
Q1
$754 Sell
2,447
-1,008
-29% -$376 ﹤0.01% 9757
2025
Q4
$1.29K Sell
3,455
-43,223
-93% -$16.3K ﹤0.01% 9638
2025
Q3
$14.9K Sell
46,678
-7,285
-13% -$2.62K ﹤0.01% 8339
2025
Q2
$13K Hold
53,963
﹤0.01% 8718
2025
Q1
$12.1K Buy
+53,963
New +$13.8K ﹤0.01% 8510

Other funds holding AFJKR

UBS Group's AFJKR Position: Q2 2026 in Review

UBS Group sold out of Aimei Health Technology Co Right (AFJKR) in Q2 2026, closing a stake of 2,447 shares — an estimated $754 sold.

UBS Group first reported a position in AFJKR in Q1 2025 and held it in 5 quarters. The position peaked at $14.9K in Q3 2025. 15 funds tracked by Wall St. Rank hold AFJKR as of Q2 2026.

  • UBS Group reported no remaining Aimei Health Technology Co Right position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 2,447 Aimei Health Technology Co Right shares in Q2 2026, an estimated $754.
  • UBS Group first reported a position in Aimei Health Technology Co Right in Q1 2025 and held it in 5 quarters.
  • UBS Group's Aimei Health Technology Co Right position peaked at $14.9K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Aimei Health Technology Co Right as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.